Bill
HD 1476
Massachusetts bill restricts non-FDA approved drug use in healthcare, requiring provider documentation and adverse event reporting to strengthen patient safety oversight.
HD 1476 restricts the use of non-FDA approved drugs in Massachusetts healthcare settings, requiring additional oversight and safety protocols before such medications can be administered to patients. The bill establishes requirements for healthcare providers to document justification when prescribing unapproved drugs and mandates reporting of adverse events to state health authorities.
Patients may currently receive medications that lack FDA approval through legitimate pathways (like compassionate use or right-to-try programs), but without standardized safety monitoring. This bill creates accountability mechanisms to track outcomes and protect vulnerable patients from potentially ineffective or harmful treatments while still preserving access to experimental options when appropriate.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
